| Ticker | Company | Sector | SS | 1Y Return | Price Target | Consensus | Analysts | HF Score | P/E |
|---|---|---|---|---|---|---|---|---|---|
| ABBV | AbbVie | Pharma | 10 | +20.8% | $255.22 | Strong Buy | 16B/4H/0S | 1.00 | ~18× |
| GOOGL | Alphabet | Technology | 10 | +121.3% | $427.50 | Strong Buy | 27B/5H/0S | 0.66 | 28.7× |
| AVGO | Broadcom | Semis | 10 | +84.6% | $480.04 | Strong Buy | 26B/4H/0S | 0.62 | 84.8× G |
| LLY | Eli Lilly | Pharma | 10 | +52.9% | $1,265.10 | Strong Buy | 20B/2H/1S | 0.65 | 39.1× |
| ASML | ASML Holding | Semis Equip | 10 | +115.9% | $1,791.40 | Strong Buy | 6B/0H/0S | 0.43 | 53.3× |
| DY | Dycom | Telecom Infra | 10 | +121.8% | $613.50+↑ | Strong Buy | 10B/0H/0S | 0.54 | ~30×* |
| ARGX | argenx SE | Biotech | 9 | +45.8% | $1,045.09 | Strong Buy | 16B/1H/0S | 0.51 | 45.4× |
| DVN | Devon+Coterra (merged) | E&P / Energy | 9 | +47.0% | $62.75 | Strong Buy | 17B/3H/0S | 0.996 | 12.2× |
| MDB | MongoDB | Cloud DB | 9 | +77.7% | $397.65 | Strong Buy | 23B/4H/0S | 0.22 | N/A |
| GH | Guardant Health | Precision Oncology | 9 | +219.3% | $131.73 | Strong Buy | 15B/1H/0S | 0.08 | N/A |
| HQY | HealthEquity | HSA Benefits | 8 | -12.5% | $121.50 | Strong Buy | 10B/0H/1S | 0.44 | 32.2× |
| SBGSY | Schneider Electric | Industrials / Electrification | 9 | +26.7% | N/A — European listing coverage | Buy | 26B/4H/0S | 0.50 | 36.5× |
| MRVL | Marvell Tech | AI Semis | 8 | +240.6% | $234.33 | Strong Buy | 26B/4H/0S | 0.11 | 71.6× G |
| Ticker | Company | Total Analysts | Buy | Hold | Sell | Buy Rate | Consensus Bar | Avg PT | PT Upside | Best Analyst |
|---|---|---|---|---|---|---|---|---|---|---|
| ABBV | AbbVie | 20 | 16 | 4 | 0 | 80% | $255.22 | ~+15% | Strong Buy | |
| GOOGL | Alphabet | 32 | 27 | 5 | 0 | 84% | $427.50 | ~+18% | Strong Buy | |
| AVGO | Broadcom | 30 | 26 | 4 | 0 | 87% | $480.04 | ~+32% | Strong Buy | |
| LLY | Eli Lilly | 23 | 20 | 2 | 1 | 87% | $1,265.10 | ~+28% | Strong Buy | |
| ASML | ASML Holding | 6 | 6 | 0 | 0 | 100% | $1,791.40 | ~+22% | Strong Buy | |
| DY | Dycom | 10 | 10 | 0 | 0 | 100% | $613.50 | ~+35% | Strong Buy | |
| ARGX | argenx | 17 | 16 | 1 | 0 | 94% | $1,045.09 | ~+18% | Strong Buy | |
| DVN | Devon Energy | 20 | 17 | 3 | 0 | 85% | $62.75 | ~+55% | Strong Buy | |
| MDB | MongoDB | 27 | 23 | 4 | 0 | 85% | $397.65 | ~+40% | Strong Buy | |
| GH | Guardant Health | 16 | 15 | 1 | 0 | 94% | $131.73 | +1.6% | Strong Buy | |
| HQY | HealthEquity | 11 | 10 | 0 | 1 | 91% | $121.50 | ~+40% | Strong Buy | |
| SBGSY | Schneider Electric | 8 recent actions | 8 | 0 | 0 | 100% | N/A | N/A | Buy | |
| MRVL | Marvell Tech | 30 | 26 | 4 | 0 | 87% | $234.33 | ~+166% | Strong Buy |
ASML and DY are the only two stocks in the cohort with a perfect 100% analyst Buy rating — zero Holds, zero Sells. ASML's monopoly on EUV lithography makes it a must-own for chip supply chain exposure. DY has unanimous bullishness on the BEAD/fiber buildout tailwind.
GOOGL (32), AVGO (30), MRVL (30), and MDB (27) have the deepest analyst coverage — mega-cap and high-growth technology companies attract the most sell-side attention and provide the most liquid price discovery.
GH is near its consensus PT after a +219% 1Y run. MRVL (~$204) has ~15% PT upside. DY surged ~31% on its Q1 FY2027 earnings beat (May 27) to ~$510 — multiple firms raised PTs, with Cantor to $654. DVN (~$36) still shows ~74% upside to the $62.75 PT as the combined Devon+Coterra entity trades at a significant discount to NAV.
HQY is the only stock with a negative 1-year return (-12.5%) despite a 91% Buy rate. This is the classic "contrarian setup" — analysts remain bullish on fundamentals while the stock has sold off. HQY's PT of $121.50 implies ~40% upside from current levels.
| Ticker | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | CAGR (4Y) | Trend |
|---|---|---|---|---|---|---|---|
| ABBV | $56,197M | $58,054M | $14,076M* | $55,300M | $58,658M | +1.1% | Stable (Humira cliff navigated) |
| GOOGL | $257,637M | $282,836M | $307,394M | $350,018M | ~$390,000M | +11.0% | Accelerating (Cloud + AI) |
| AVGO | $27,450M | $33,203M | $35,819M | $51,574M | ~$60,000M | +21.7% | Accelerating (VMware + AI) |
| LLY | $28,318M | $28,541M | $34,124M | $45,042M | ~$58,000M | +19.6% | Accelerating (GLP-1 ramp) |
| ASML | €15,978M | €21,173M | €27,559M | €28,261M | ~€30,000M | +17.1% | Strong (EUV cycle) |
| DY | $3,323M | $3,654M | $4,487M | $5,094M | ~$6,200M | +17.0% | Accelerating (BEAD/fiber) |
| ARGX | €196M | €627M | €1,430M | €2,956M | €4,154M | +115.5% | Hypergrowth (VYVGART ramp) |
| DVN | $12,213M | $19,189M | $14,919M | $14,626M | ~$12,800M | +1.2% | Cyclical (oil price driven) |
| MDB | $590M | $874M | $1,284M | $1,682M | $2,009M | +35.9% | Strong (Atlas growth) |
| GH | $374M | $450M | $564M | $739M | $982M | +27.3% | Accelerating (Shield FDA) |
| HQY | $632M | $788M | $895M | $1,086M | ~$1,250M | +18.6% | Steady (HSA growth) |
| SBGSY | €28,900M | €34,200M | €35,900M | €38,200M | €40,200M | +8.6% | Steady compounder (electrification + automation) |
| MRVL | $2,972M | $5,518M | $5,921M | $5,510M | $8,225M | +29.1% | Accelerating (AI ASIC) |
*ABBV FY2023 impacted by Allergan purchase accounting adjustments. ARGX and SBGSY figures in EUR. DY/MDB/HQY/MRVL: FY = Feb–Jan.
| Ticker | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | Direction | Commentary |
|---|---|---|---|---|---|---|---|
| ABBV | ~18% | ~19% | ~22% | ~23% | ~24% | ↑ Improving | Humira biosimilar erosion offset by Skyrizi/Rinvoq ramp |
| GOOGL | ~29% | ~21% | ~24% | ~26% | ~32.8% | ↑ Improving | Cost cuts + AI-driven monetization; record margins |
| AVGO | ~22% | ~24% | ~26% | ~11% | ~36.2% | ↑ Strong | FY2024 dip from VMware acquisition; recovered strongly |
| LLY | ~19% | ~16% | ~18% | ~22% | ~31.7% | ↑ Accelerating | GLP-1 manufacturing scale driving operating leverage |
| ASML | ~26% | ~29% | ~31% | ~27% | ~29.4% | ↑ Stable/High | Consistently ~27–31%; EUV monopoly pricing power |
| DY | ~3% | ~3.5% | ~4% | ~4.5% | ~5.1% | ↑ Improving | Low-margin contractor, but steadily expanding |
| ARGX | N/M (loss) | -36% | -16% | ~15% | ~31.1% | ↑ Hyperjump | Flipped to GAAP profitability in FY2024; massive improvement |
| DVN | ~16% | ~34% | ~23% | ~16% | ~13% | ↓ Cyclical | Tied to WTI oil prices; compressed by lower commodity prices |
| MDB | -37% | -56% | -28% | -15% | -8% | ↑ Improving | Still GAAP-negative but narrowing fast; Non-GAAP positive |
| GH | -109% | -146% | -85% | -59% | -42% | ↑ Improving | Pre-profitability; loss narrowing consistently |
| HQY | ~10% | ~12% | ~13% | ~16% | ~17% | ↑ Steady | Predictable margin expansion from custodial yield leverage |
| SBGSY | ~11.1% | ~10.2% | ~11.2% | ~11.2% | ~10.4% | → Stable | High-quality industrial software/electrification mix; EBIT margin expanding |
| MRVL | ~6% | ~8% | ~5% | ~2.5% | ~36.2% | ↑ Surge | AI ASIC revenue transformed mix; massive margin expansion in FY2025 |
| Ticker | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | Trend |
|---|---|---|---|---|---|---|
| ABBV | $22,100M | $21,400M | $22,800M | $24,100M | ~$26,000M | ↑ FCF Machine |
| GOOGL | $67,012M | $60,010M | $69,495M | $72,764M | ~$73,300M | ↑ Massive & Growing |
| AVGO | ~$14,100M | ~$16,300M | ~$17,600M | ~$19,400M | ~$26,900M | ↑ Expanding |
| LLY | ~$5,800M | ~$5,300M | -$3,150M | ~$8,200M | ~$9,000M | ↑ (FY2023 capex dip) |
| ASML | €4,000M | €6,100M | €7,500M | €6,000M | ~€10,600M | ↑ Strong |
| DY | ~$180M | ~$250M | ~$310M | ~$360M | ~$402M | ↑ Steady Growth |
| ARGX | -€800M | -€900M | -€400M | ~€200M | ~€700M | ↑ Turned Positive |
| DVN | ~$1,800M | ~$4,600M | ~$3,800M | ~$2,900M | ~$2,100M | ↓ Cyclically Compressing |
| MDB | ~$25M | ~$100M | ~$260M | ~$420M | ~$500M | ↑ Compounding |
| GH | -$284M | -$387M | -$345M | -$275M | -$233M | ↑ Improving (still negative) |
| HQY | ~$200M | ~$280M | ~$350M | ~$410M | ~$455M | ↑ Steady Compounder |
| SBGSY | €2,700M | €3,300M | €4,500M | €4,600M | €4,900M | ↑ Best-in-class industrial FCF growth |
| MRVL | ~$900M | ~$1,500M | ~$1,700M | ~$1,600M | ~$3,200M | ↑ Surge (AI mix shift) |
| Segment | Q1 2026 Revenue | YoY Growth | % of Total | Trend Commentary |
|---|---|---|---|---|
| Google Search & Other | ~$54B | +12% | ~54% | Resilient core; AI Overviews enhancing query monetization |
| Google Cloud | ~$12.3B | +28% | ~12% | Fastest-growing segment; AI workloads accelerating; approaching $50B run rate |
| YouTube Ads | ~$8.9B | +10% | ~9% | Steady growth; Shorts monetization improving |
| Google Network | ~$7.3B | -3% | ~7% | Secular decline as programmatic shifts to first-party channels |
| Other Bets & Services | ~$17.4B | +9% | ~17% | Google One, Pixel, Waymo milestones; subscription growth |
| Segment | Q1 FY26 Revenue | YoY Growth | % of Total | Trend Commentary |
|---|---|---|---|---|
| AI Semiconductors | ~$4.1B | +77% | ~26% | XPUs for hyperscaler AI clusters; Google TPU, Meta MTIA; largest growth vector |
| Infrastructure Software (VMware) | ~$6.7B | +47% | ~42% | VMware integration ahead of plan; subscription conversion ongoing |
| Networking (Non-AI) | ~$3.2B | +8% | ~20% | Enterprise networking recovery; data center switching |
| Storage / Other | ~$1.9B | -5% | ~12% | Legacy storage declining; focus shifting to AI workloads |
| Product / Segment | Q1 2026 Revenue | YoY Growth | % of Total | Trend Commentary |
|---|---|---|---|---|
| Mounjaro (tirzepatide) — T2D | ~$3.8B | +65% | ~26% | Core GLP-1 product; international approvals expanding |
| Zepbound (tirzepatide) — Obesity | ~$2.6B | +New | ~18% | Fastest new drug launch in pharma history; supply now ramping |
| Verzenio (abemaciclib) | ~$1.2B | +18% | ~8% | Breast cancer CDK4/6 inhibitor; growing market share vs. Ibrance |
| Taltz / Jardiance / Other | ~$6.9B | +6% | ~47% | Diversified portfolio; steady contributors |
| Segment | Q1 FY26 Revenue | YoY Growth | % of Total | Trend Commentary |
|---|---|---|---|---|
| AI / Data Center | ~$1.7B | +90%+ | ~62% | Custom AI ASICs (XPUs) for hyperscalers + 800G PAM4 DSPs; structural shift |
| Carrier / Enterprise Networking | ~$580M | +12% | ~21% | Recovering from cyclical downturn; 5G spend normalizing |
| Storage / Other | ~$460M | -8% | ~17% | Legacy declining; MRVL de-emphasizing non-AI hardware |
| Segment (as reported) | Q1 2026 Revenue | YoY Growth | % of Total | Trend Commentary |
|---|---|---|---|---|
| Oncology (G360 + Reveal combined) | $205.0M | +36% | 68% | Core franchise; therapy selection + MRD; ~86K tests (+47% volume YoY) |
| Screening (Shield — blood CRC test) | $41.6M | +600%+ | 14% | FDA-approved July 2024; ramping from near-zero; accelerating with every new payer coverage win |
| Biopharma & Data | $53.0M | +17% | 18% | Pharma clinical trial testing + data licensing; stable recurring revenue |
Q1 2026 total: $301.7M (+48.3% YoY). GH raised FY2026 guidance to $1.30–$1.32B (+32–34%). Source: GH Q1 2026 Earnings Release, May 7, 2026.
| Segment | Q1 FY26 Revenue | YoY Growth | % of Total | Trend Commentary |
|---|---|---|---|---|
| Atlas (Cloud / Multi-Cloud) | ~$375M | +35% | ~72% | Primary growth driver; consumption-based pricing leverages AI workloads |
| Enterprise Advanced (on-prem) | ~$145M | -5% | ~28% | Legacy perpetual licenses declining; management guiding customers to Atlas |
| Ticker | Growth | Quality / Moat | Profitability | Analyst Sentiment | Technicals | Valuation | TAM / Position | OVERALL | Verdict |
|---|---|---|---|---|---|---|---|---|---|
| ABBV | 7.5 | 9.0 | 9.5 | 8.5 | 8.0 | 8.0 | 8.5 | ~8.5 | Top compounder; Skyrizi/Rinvoq transition ahead of schedule. Dividend + buyback fortress. |
| GOOGL | 8.5 | 9.5 | 9.5 | 9.0 | 8.0 | 8.5 | 9.0 | 8.4 | AI re-rating in progress. Cloud + Gemini. FCF $73B. Reasonable 28.7× for compounding quality. |
| AVGO | 9.0 | 9.0 | 9.0 | 9.0 | 8.0 | 7.5 | 9.0 | 8.6 | AI ASIC + VMware integration = premium franchise. Best-in-class FCF per share growth. |
| LLY | 9.5 | 9.0 | 8.5 | 9.0 | 7.5 | 7.0 | 9.5 | 8.3 | GLP-1 mega-cycle. Obesity + T2D TAM = multi-trillion. Capex buildout nearing completion. |
| ASML | 9.0 | 10.0 | 9.0 | 10.0 | 8.0 | 7.5 | 9.5 | 8.6 | Irreplaceable EUV monopoly. Every advanced chip made anywhere uses ASML machines. Generational moat. |
| DY | 8.5 | 7.5 | 7.0 | 9.5 | 7.0 | 6.5 | 7.5 | 7.4 | BEAD/fiber play. Q1 FY2027: $1.965B rev (+56% YoY), EPS $4.42 vs $2.72 est. Backlog $11.9B, book-to-bill 2.2×. FY27 guidance $7.38-$7.65B. 100% Buy consensus. |
| ARGX | 9.5 | 8.5 | 8.0 | 9.0 | 7.5 | 7.0 | 8.5 | 8.0 | VYVGART (efgartigimod) commercial explosion. Flipped to GAAP profitability. Pipeline loaded. |
| DVN | 5.0 | 7.0 | 7.5 | 8.5 | 5.0 | 8.5 | 6.0 | 7.0 | Cheapest stock in cohort (P/E 12.2×). Highest HF Score (0.996). SELL tech signal. Commodity risk. |
| MDB | 9.0 | 8.5 | 7.0 | 9.0 | 7.5 | 7.0 | 8.5 | 8.1 | Atlas 72% of revenue. Developer-first flywheel. FCF $500M+. AI vector search = new catalyst. |
| GH | 9.5 | 8.0 | 7.0 | 9.0 | 6.5 | 6.0 | 9.0 | 7.9 | +219% 1Y. Shield FDA-approved, ramp underway. At consensus PT — entry risk elevated post-run. |
| HQY | 7.5 | 8.0 | 8.0 | 8.0 | 6.5 | 8.5 | 7.5 | 7.6 | Only negative 1Y return. Contrarian setup — 91% Buy rate, ~40% upside to PT. HSA custodian moat. |
| SBGSY | 8.0 | 9.0 | 8.5 | 8.5 | 8.0 | 7.0 | 9.0 | 8.2 | Pure-play electrification, automation, data-center power, and AI infrastructure exposure. High-quality European industrial compounder. |
| MRVL | 9.5 | 8.5 | 7.0 | 9.0 | 8.0 | 6.5 | 9.0 | 7.9 | Best 1Y performer (+240.6%). AI ASIC 62% of revenue. Non-GAAP PE ~36× more reasonable than 71.6× GAAP. |
| 1. | AVGO | 8.6/10 |
| 1. | ASML | 8.6/10 |
| 3. | ABBV | ~8.5/10 |
| 4. | GOOGL | 8.4/10 |
| 5. | LLY | 8.3/10 |
| 1. | MRVL | +240.6% |
| 2. | GH | +219.3% |
| 3. | DY | +121.8% |
| 4. | GOOGL | +121.3% |
| 5. | ASML | +115.9% |
| 1. | DVN | P/E 12.2×, HF 0.996 |
| 2. | HQY | ~40% PT upside |
| 3. | ABBV | Dividend yield + buyback |
| 4. | GOOGL | 28.7× for quality |
| 5. | MDB | ~40% PT upside |